An international study led by Peter Mac has revealed the origin of mucinous ovarian cancer (MOC) confirming, unlike other types of ovarian cancer, this rare cancer is not seeded from elsewhere in the body.
Peter MacCallum Cancer Centre welcomes the issuing of the first license to manufacture commercial T-Cell treatments, including breakthrough CAR T-Cell therapies, within Australia. The Therapeutic Goods Administration has awarded a T-Cells GMP manufacturing licence to Cell Therapies Pty Ltd, a company which is situated at Peter Mac.
Groundbreaking research projects led by Peter Mac scientists and clinician researchers have attracted more than $19 million in the latest round of NHMRC grants. The funded projects include a major study of the role of vasculature in cancer progression, research into improved infection control in cancer patients, and improving the effectiveness of immunotherapies and personalised cancer treatments.
Peter Mac scientists working with the drug company Senhwa Biosciences have developed a new way to target cancer, and have demonstrated it can stall disease progression in patients who are no longer responding to conventional treatments.
Peter Mac Research is gaining two new star recruits this month. Prof Ben Hogan and A/Prof Belinda Parker will join the Peter Mac team, bringing with them their world-leading research into the way that cancers can spread and respond to different types of treatments.
The Peter MacCallum Cancer Centre acknowledges the traditional
owners of the land on which our five sites are located throughout Victoria.
We recognise their strength and resilience and pay our respects
to their Elders past and present.